BMS-986158 NEW
| Price | $79 | $272 | $396 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-07-14 |
Product Details
| Product Name: BMS-986158 | CAS No.: 1800340-40-2 |
| Purity: 99.45% | Supply Ability: 10g |
| Release date: 2026/07/14 |
Product Introduction
Bioactivity
| Name | BMS-986158 |
| Description | BMS-986158 is a highly effective BET inhibitor, demonstrating IC50 values of 6.6 nM in NCI-H211 small cell lung cancer (SCLC) cells and 5 nM in MDA-MB231 triple negative breast cancer (TNBC) cells. |
| In vitro | BMS-986158 acts as an inhibitor targeting the bromodomain (BRD) and extra-terminal domain (BET) protein family, offering potential for cancer treatment. When administered, BMS-986158 attaches to the BRD's acetyl-lysine binding site on BET proteins, blocking their interaction with acetylated histones. This interruption hampers chromatin remodeling and curbs the expression of genes that promote growth, thereby inhibiting tumor cell proliferation[2]. |
| Storage | Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 60 mg/mL (121.06 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.04 mM), Sonication is recommended. |
| Keywords | Inhibitor | inhibit | EpigeneticReaderDomain | Epigenetic Reader Domain | BMS-986158 | BMS986158 | BMS 986158 | BET |
| Inhibitors Related | ABBV-744 | CeMMEC1 | 3-methyl-1,2,3,4-tetrahydroquinazolin-2-one | (+)-JQ-1 | J-147 | 5-Ph-IAA | Curcumin | dBET6 | Naphthol AS-E | Revumenib | JQ-1 (carboxylic acid) | Bisdemethoxycurcumin |
| Related Compound Libraries | Anti-Lung Cancer Compound Library | Histone Modification Compound Library | Bioactive Compound Library | ReFRAME Related Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Clinical Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $545.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-07-27 | |
| $2180.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-05-21 | |
|
VIP3Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2026-08-06 | ||
| $79.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-07-14 | |
|
VIP4Y
|
Henan Aochuang Chemical Co.,Ltd.
|
2025-04-04 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY